Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Research and Markets: Cubist's CXA-201 - A Novel Antibiotic for Gram-negative Infections

Research and Markets
Posted on: 12 Oct 12

Research and Markets ( has announced the addition of the "Cubist's CXA-201 - A novel antibiotic for Gram-negative infections" report to their offering.

Cubist's CXA-201 is a first-line intravenous antibiotic combination of a novel cephalosporin (CXA-101) and a generic ß-lactamase inhibitor - tazobactam - for the treatment of serious Gram negative bacterial infections. CXA-201 does not have a completely new mechanism of action, and it is not active against all mechanisms of resistance, but it offers enhanced activity against some key resistant Gram negative pathogens, and particularly strong activity against P. aeruginosa. This report reviews CXA-201's clinical profile and potential, emerging competition, as well as the market opportunity and commercial prospects for this new antibiotic in the empirical Gram negative treatment setting.

Key Topics Covered:


1. The growing problem of antibiotic resistance

2. Gram negative bacteria

- Gram negative nosocomial Infections

3. Main mechanisms of resistance in Gram negative bacteria

- ß-lactamase production - the most prevalent resistance mechanism

- Various resistance mechanisms influence each other

4. Pseudomonas aeruginosa and mechanisms of resistance

5. Treatment recommendations for Gram negative infections

6. The role of beta lactam antibiotics/ß-lactamase inhibitor combinations


1. CXA-101

- Microbiologic assessment

- Pharmacokinetics

- Phase II trial of CXA-101 in cUTI

2. CXA-201

- Animal proof-of-concept study

- Pharmacokinetics of CXA-201

- CXA-201 phase II trial in cIAI recently completed

3. Pivotal Phase III trials in cUTI


1. How strong is the rationale

2. What can we learn from the in vitro testing

3. Predictors of clinical efficacy

4. The profile of CXA-101 as a stand-alone agent

5. CXA-201 broadens coverage but holes remain

6. Current us regulatory considerations


1. Novel ß-lactam antibiotic/ ß -lactamase inhibitor combinations

- NXL104 (Avibactam; AstraZeneca and Forest Laboratories):

2. Novel antibiotics targeting Gram negative infections

3. Pipeline products targeting Pseudomonas aeruginosa


1. Less Profit, Fewer Drugs

2. CXA-201's revenue potential

3. Empirical treatment market opportunity


Companies Mentioned

- AstraZeneca

- Forest Laboratories

- MerLIon Pharmaceuticals

- NovaBay Pharmaceuticals

- Basilea

- Anacor

- Glaxo-Smith-Kline

- Achaogen

- SelectX Pharmaceuticals

- Theravance

- Gilead

- KaloBios

- Sanofi Pasteur

For more information visit

Business Wire

Last updated on: 12/10/2012

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.